The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment
Yoshihiko Sakata(Saiseikai Kumamoto Hospital), Kodai Kawamura(Saiseikai Kumamoto Hospital), Kazuya Ichikado(Saiseikai Kumamoto Hospital), Naoki Shingu(Saiseikai Kumamoto Hospital), Yuko Yasuda(Saiseikai Kumamoto Hospital), Yoshitomo Eguchi(Saiseikai Kumamoto Hospital), Keisuke Anan(Saiseikai Kumamoto Hospital), Junpei Hisanaga(Saiseikai Kumamoto Hospital), Tatsuya Nitawaki(Saiseikai Kumamoto Hospital), Miwa Iio(Saiseikai Kumamoto Hospital), Yuko Sekido(Saiseikai Kumamoto Hospital), Aiko Nakano(Saiseikai Kumamoto Hospital), Takuro Sakagami(Kumamoto University Hospital)
Cited by 43
Abstract
Related Papers
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al.|Journal of the National Comprehensive Cancer Network|2017|1.3k